Compounds > galantamine

galantamine and Vomiting

galantamine has been researched along with Vomiting in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kertesz, A1
Brashear, HR; Dunbar, F; Zhu, Y1
Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP1
Gallini, A; Montastruc, JL; Salandini, AM; Sommet, A; Veyssière, P1
Wong, VS1

Trials

2 trial(s) available for galantamine and Vomiting

ArticleYear
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.
    Current neurology and neuroscience reports, 2002, Volume: 2, Issue:6

    Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Double-Blind Method; Galantamine; Humans; Nausea; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Vomiting

2002
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Clinical therapeutics, 2006, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiemetics; Cholinesterase Inhibitors; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Middle Aged; Nausea; Vomiting

2006

Other Studies

4 other study(ies) available for galantamine and Vomiting

ArticleYear
In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.
    International journal of pharmaceutics, 2007, Apr-20, Volume: 335, Issue:1-2

    Topics: Administration, Intranasal; Administration, Oral; Analysis of Variance; Animals; beta-Cyclodextrins; Biological Availability; Cell Membrane Permeability; Cells, Cultured; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Compounding; Edetic Acid; Electric Impedance; Epithelial Cells; Excipients; Factor Analysis, Statistical; Ferrets; Galantamine; Humans; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Respiratory Mucosa; Tight Junctions; Vomiting

2007
Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-15, Volume: 22, Issue:13

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Anorexia; Antiparkinson Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Galantamine; Humans; Lewy Body Disease; Memantine; Mental Status Schedule; Nausea; Nootropic Agents; Parkinson Disease; Vomiting; Weight Loss

2007
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
    Neurology, 2007, Aug-21, Volume: 69, Issue:8

    Topics: Alzheimer Disease; Caregivers; Clinical Trials as Topic; Disability Evaluation; Galantamine; Humans; Memory Disorders; Neuropsychological Tests; Nootropic Agents; Outcome Assessment, Health Care; Quality of Life; Respiratory Tract Infections; Risk Assessment; Speech Disorders; Treatment Outcome; Verbal Behavior; Vomiting

2007
Galantamine (reminyl) for Alzheimer's disease.
    The Medical letter on drugs and therapeutics, 2001, Jun-25, Volume: 43, Issue:1107

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Galantamine; Humans; Nausea; Vomiting

2001